Loading
Four groups defined by a few tests that predict outcome better than the microscope: POLE-mutated (excellent), mismatch-repair deficient, p53-abnormal (worst), and 'no specific profile'.
From TCGA (Nature 2013) via the ProMisE classifier (Talhouk 2015) into the WHO 2020 classification and ESGO/ESTRO/ESP 2021 guidelines. POLE-ultramutated (~7%) almost never relapses and may need no adjuvant therapy; MMRd (~25-30%) responds to immunotherapy; p53abn (~15%; includes most serous) benefits from chemotherapy (PORTEC-3) and often carries HER2 amplification; NSMP (~50%) is heterogeneous, with L1CAM and ER status refining risk. Molecular-class-directed adjuvant trials (RAINBO programme, PORTEC-4a) are ongoing.
In plain words · TP53 is the 'guardian of the genome', broken in half of all cancers. Fixing it directly has so far defeated every attempt, so drugs exploit what its loss makes cancers depend on.
Showing the target this term concerns: TP53.
Shares PORTEC-3, POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma, Mismatch-repair-deficient endometrial cancer.
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer with no specific molecular profile, Mismatch-repair-deficient endometrial cancer.
Shares HER2 ADCs as standard for HER2-positive serous endometrial cancer, POLE ultramutation (POLEmut), PORTEC-3, POLE-ultramutated endometrial cancer.
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer with no specific molecular profile, Mismatch-repair-deficient endometrial cancer.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer with no specific molecular profile, Mismatch-repair-deficient endometrial cancer, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
Shares VENTANA MMR RxDx Panel, Mismatch repair & microsatellite instability, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), TP53.
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile, Endometrial cancer.
Shares PORTEC-3, p53-abnormal endometrial cancer, including uterine serous carcinoma.